HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Serum Metabolomic Alterations Associated with Proteinuria in CKD.

AbstractBACKGROUND AND OBJECTIVES:
Data are scarce on blood metabolite associations with proteinuria, a strong risk factor for adverse kidney outcomes. We sought to investigate associations of proteinuria with serum metabolites identified using untargeted profiling in populations with CKD.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:
Using stored serum samples from the African American Study of Kidney Disease and Hypertension (AASK; n=962) and the Modification of Diet in Renal Disease (MDRD) study (n=620), two rigorously conducted clinical trials with per-protocol measures of 24-hour proteinuria and GFR, we evaluated cross-sectional associations between urine protein-to-creatinine ratio and 637 known, nondrug metabolites, adjusting for key clinical covariables. Metabolites significantly associated with proteinuria were tested for associations with CKD progression.
RESULTS:
In the AASK and the MDRD study, respectively, the median urine protein-to-creatinine ratio was 80 (interquartile range [IQR], 28-359) and 188 (IQR, 54-894) mg/g, mean age was 56 and 52 years, 39% and 38% were women, 100% and 7% were black, and median measured GFR was 48 (IQR, 35-57) and 28 (IQR, 18-39) ml/min per 1.73 m2. Linear regression identified 66 serum metabolites associated with proteinuria in one or both studies after Bonferroni correction (P<7.8×10-5), 58 of which were statistically significant in a meta-analysis (P<7.8×10-4). The metabolites with the lowest P values (P<10-27) were 4-hydroxychlorthalonil and 1,5-anhydroglucitol; all six quantified metabolites in the phosphatidylethanolamine pathway were also significant. Of the 58 metabolites associated with proteinuria, four were associated with ESKD in both the AASK and the MDRD study.
CONCLUSIONS:
We identified 58 serum metabolites with cross-sectional associations with proteinuria, some of which were also associated with CKD progression.
PODCAST:
This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_02_07_CJASNPodcast_19_03_.mp3.
AuthorsShengyuan Luo, Josef Coresh, Adrienne Tin, Casey M Rebholz, Lawrence J Appel, Jingsha Chen, Ramachandran S Vasan, Amanda H Anderson, Harold I Feldman, Paul L Kimmel, Sushrut S Waikar, Anna Köttgen, Anne M Evans, Andrew S Levey, Lesley A Inker, Mark J Sarnak, Morgan Erika Grams, Chronic Kidney Disease Biomarkers Consortium Investigators
JournalClinical journal of the American Society of Nephrology : CJASN (Clin J Am Soc Nephrol) Vol. 14 Issue 3 Pg. 342-353 (03 07 2019) ISSN: 1555-905X [Electronic] United States
PMID30733224 (Publication Type: Journal Article, Observational Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2019 by the American Society of Nephrology.
Chemical References
  • Biomarkers
Topics
  • Black or African American
  • Biomarkers (blood)
  • Clinical Trials as Topic
  • Cross-Sectional Studies
  • Disease Progression
  • Energy Metabolism
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Kidney (physiopathology)
  • Male
  • Metabolomics
  • Middle Aged
  • Proteinuria (blood, diagnosis, ethnology, physiopathology)
  • Renal Insufficiency, Chronic (blood, diagnosis, ethnology, physiopathology)
  • United States (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: